Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Prabhjot S. Mundi"'
Autor:
Prabhjot S. Mundi, Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey, Kristina Guillan, Armaan Siddiquee, Daoqi You, Ronald Realubit, Charles Karan, Michael V. Ortiz, Eugene F. Douglass, Melissa Accordino, Suzanne Mistretta, Frances Brogan, Jeffrey N. Bruce, Cristina I. Caescu, Richard D. Carvajal, Katherine D. Crew, Guarionex Decastro, Mark Heaney, Brian S. Henick, Dawn L. Hershman, June Y. Hou, Fabio M. Iwamoto, Joseph G. Jurcic, Ravi P. Kiran, Michael D. Kluger, Teri Kreisl, Nicole Lamanna, Andrew B. Lassman, Emerson A. Lim, Gulam A. Manji, Guy M. McKhann, James M. McKiernan, Alfred I. Neugut, Kenneth P. Olive, Todd Rosenblat, Gary K. Schwartz, Catherine A. Shu, Michael B. Sisti, Ana Tergas, Reena M. Vattakalam, Mary Welch, Sven Wenske, Jason D. Wright, Peter Canoll, Hanina Hibshoosh, Kevin Kalinsky, Mahalaxmi Aburi, Peter A. Sims, Mariano J. Alvarez, Andrew L. Kung, Andrea Califano
Publikováno v:
Cancer Discovery. :OF1-OF22
Predicting in vivo response to antineoplastics remains an elusive challenge. We performed a first-of-kind evaluation of two transcriptome-based precision cancer medicine methodologies to predict tumor sensitivity to a comprehensive repertoire of clin
Autor:
Kevin Kalinsky, Melissa K. Accordino, Codruta Chiuzan, Prabhjot S. Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S. Trivedi, Yelena Novik, Amy Tiersten, George Raptis, Lea N. Baer, Sun Y. Oh, Amelia B. Zelnak, Kari B. Wisinski, Eleni Andreopoulou, William J. Gradishar, Erica Stringer-Reasor, Sonya A. Reid, Anne O'Dea, Ruth O'Regan, Katherine D. Crew, Dawn L. Hershman
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–)
Data from Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Autor:
Jennifer E. Amengual, Olivier Elemento, Neil L. Kelleher, Serge Cremers, Renu Nandakumar, Changhong Qiao, Emily I. Chen, Swasti Mehta, Jeannie M. Camarillo, Nebiyu Abshiru, Prabhjot S. Mundi, Akanksha Verma, Yulissa Gonzalez, Yuxuan Liu, Sathyen A. Prabhu, Jennifer K. Lue
Purpose:Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been implicated in the pathogenesis of germinal center (GC)–derived lymphomas. We hypot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c25494f751d349c18a9a0f314e919e
https://doi.org/10.1158/1078-0432.c.6527655
https://doi.org/10.1158/1078-0432.c.6527655
Autor:
Jennifer E. Amengual, Olivier Elemento, Neil L. Kelleher, Serge Cremers, Renu Nandakumar, Changhong Qiao, Emily I. Chen, Swasti Mehta, Jeannie M. Camarillo, Nebiyu Abshiru, Prabhjot S. Mundi, Akanksha Verma, Yulissa Gonzalez, Yuxuan Liu, Sathyen A. Prabhu, Jennifer K. Lue
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3a7acc7afb6706436cb46f252d3e0a
https://doi.org/10.1158/1078-0432.22470681
https://doi.org/10.1158/1078-0432.22470681
Autor:
Prabhjot S Mundi, Arsenije Kojadinovic
Publikováno v:
Clinical Colorectal Cancer. 20:e249-e252
Autor:
Prabhjot S. Mundi, Filemon S. Dela Cruz, Michael V. Ortiz, Adina Grunn, Daniel Diolaiti, Mariano J. Alvarez, Andrew L. Kung, Andrea Califano
Publikováno v:
Cancer Research. 83:849-849
Background: Predicting in vivo response to antineoplastics remains an elusive challenge. We evaluated two novel transcriptomic-based, tumor-agnostic systems biology tools, OncoTarget and OncoTreat. Both methodologies predict tumor response to a diver
Autor:
Susan E. Bates, Yeun-Hee Anna Park, Grace Clarke Hillyer, Ta-Chueh Hsu Rosenberg, Imtiaz Patel, Prabhjot S. Mundi
Publikováno v:
Semin Oncol
BACKGROUND: Participation in clinical trials is essential to bringing novel and innovative cancer treatments to the bedside but trials that specifically enroll Veterans are relatively few. Given the inherent differences between Veterans and the gener
Publikováno v:
Journal of the Endocrine Society. 6:A163-A164
Hypercalcemia is a relatively common clinical problem. Among all causes of hypercalcemia, primary hyperparathyroidism and malignancy are the most common. This case highlights the importance of collaboration between subspecialists to identify the etio
Publikováno v:
Critical Reviews in Oncology/Hematology. 181:103882
Genomic alterations in the receptor tyrosine kinase RET represent actionable driver events in several cancer types. Activation of the kinase domain by point mutations represents a pathognomonic event in medullary thyroid cancer, while RET fusions are
Publikováno v:
Cureus.